PMID- 12658908
OWN - NLM
STAT- MEDLINE
DCOM- 20030708
LR  - 20191106
IS  - 0043-5325 (Print)
IS  - 0043-5325 (Linking)
VI  - 115
IP  - 1-2
DP  - 2003 Jan 31
TI  - Clinicopathologic profile of gestational trophoblastic disease.
PG  - 29-35
AB  - Much debate exists on factors predicting the development of persistent 
      gestational trophoblastic disease (pGTD). Diagnosis is still limited by following 
      persistently elevated or rising postevacutation beta-human chorionic gonadotropin 
      (beta-hCG) titers. The aim of the present work was to evaluate the hypothesis 
      that the presence of c-erbB-2 oncogene amplification and expression, in 
      combination with parameters such as DNA-content and karyotype of the sex 
      chromosomes, confer an increased risk of developing pGTD. Clinicopathological 
      characteristics were evaluated in 36 cases of gestational trophoblastic diseases 
      (GTD) and analyzed for c-erbB-2 amplification and protein p185 expression using 
      differential polymerase chain reaction (DPCR) and immunohistochemical (IHC) 
      techniques. The DNA-content was determined by image analysis on Feulgen stained 
      nuclear cell preparations and karyotyping for XY chromosomes was performed by 
      fluorescence in situ hybridization (FISH). The data was correlated with 
      histopathological characteristics of GTD. Seventy-five percent (n = 27) of the 
      examined cases showed spontaneous regression after evacuation, including 2 
      patients who received additional chemotherapy. Twenty-five percent (n = 9) 
      resulted in a persistent or metastatic disease. The median time between 
      antecedent pregnancy and GTD was 45.4 months. Complete remission was achieved in 
      all patients with pGTD after administration of chemotherapeutic agents or 
      adjuvant surgical procedures. Cases with cerbB-2 amplification and expression in 
      combination with DNA hyperploidy showed higher proliferation and more aggressive 
      behavior (2 complete hydatidiform moles with lung and liver metastases, 2 
      invasive moles and 1 choriocarcinoma). XY karyotype was evident in the 
      choriocarcinoma and in 2 complete hydatidiform moles with advanced stage and DNA 
      hyperploidy. From these results we conclude that c-erbB-2 amplification and/or 
      protein expression in combination with DNA-content show a significant correlation 
      with the proliferative and aggressive potential of GTD, suggesting their combined 
      use as a possible marker for pGTD.
FAU - Jelincic, Darko
AU  - Jelincic D
AD  - Division of Prenatal Diagnostics and Therapy, University of Vienna, Vienna, 
      Austria.
FAU - Hudelist, Gernot
AU  - Hudelist G
FAU - Singer, Christian Fridolin
AU  - Singer CF
FAU - Bauer, Margit
AU  - Bauer M
FAU - Horn, Lars Christian
AU  - Horn LC
FAU - Bilek, Karin
AU  - Bilek K
FAU - Czerwenka, Klaus
AU  - Czerwenka K
LA  - eng
PT  - Journal Article
PL  - Austria
TA  - Wien Klin Wochenschr
JT  - Wiener klinische Wochenschrift
JID - 21620870R
RN  - 0 (Chorionic Gonadotropin, beta Subunit, Human)
RN  - 0 (DNA, Neoplasm)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Austria
MH  - Chorionic Gonadotropin, beta Subunit, Human/blood
MH  - Combined Modality Therapy
MH  - DNA, Neoplasm/genetics
MH  - Female
MH  - Follow-Up Studies
MH  - Gene Expression Regulation, Neoplastic/physiology
MH  - Genes, erbB-2/genetics
MH  - Genetic Predisposition to Disease/genetics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Karyotyping
MH  - Ploidies
MH  - Polymerase Chain Reaction
MH  - Pregnancy
MH  - Receptor, ErbB-2/genetics
MH  - Trophoblastic Neoplasms/*diagnosis/genetics/pathology/therapy
MH  - Uterine Neoplasms/*diagnosis/genetics/pathology/therapy
MH  - Uterus/pathology
EDAT- 2003/03/28 05:00
MHDA- 2003/07/09 05:00
CRDT- 2003/03/28 05:00
PHST- 2003/03/28 05:00 [pubmed]
PHST- 2003/07/09 05:00 [medline]
PHST- 2003/03/28 05:00 [entrez]
AID - 10.1007/BF03040269 [doi]
PST - ppublish
SO  - Wien Klin Wochenschr. 2003 Jan 31;115(1-2):29-35. doi: 10.1007/BF03040269.